Jinlin Song1, Elyse Swallow2, Qayyim Said3, Miranda Peeples1, Mark Meiselbach1, James Signorovitch1, Michael Kohrman4, Bruce Korf5, Darcy Krueger6, Michael Wong7, Steven Sparagana8. 1. Analysis Group, Inc., 111 Huntington Ave, Floor 14, Boston, MA 02199, United States. 2. Analysis Group, Inc., 111 Huntington Ave, Floor 14, Boston, MA 02199, United States. Electronic address: elyse.swallow@analysisgroup.com. 3. Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ 07936, United States. 4. Akron Children's Hospital, 1 Perkins Square, Akron, OH 44308, United States. 5. University of Alabama at Birmingham, 1720 2(nd) Ave S, Birmingham, AL 35294, United States. 6. Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, United States. 7. Washington University in Saint Louis, 1 Brookings Dr, St. Louis, MO 63130, United States. 8. Texas Scottish Rite Hospital for Children, 2222 Wellborn St, Dallas, TX 75219, United States.
Abstract
INTRODUCTION: Tuberous sclerosis complex (TSC) is a rare congenital disorder often associated with epilepsy. However, real-world treatment patterns for epilepsy in patients with TSC are not yet well categorized. METHODS: This study included patients with TSC and epilepsy from fifteen clinics in the United States and one in Belgium who were enrolled in the TSC Natural History Database (2006-2014). Patient demographics and epilepsy treatment patterns, including the use of anti-epileptic drugs (AEDs), epilepsy surgeries, and dietary therapies were assessed. RESULTS: Of the 1328 patients with TSC in the database, 1110 (83.6%) were diagnosed with epilepsy. The median age of epilepsy diagnosis was 0.7 years. Of those who received treatment for epilepsy (92.3%), 99.5% were prescribed AEDs, 25.3% underwent surgery, 7.9% were prescribed special diets, and 1% were prescribed mammalian target of rapamycin (mTOR) inhibitors. Of the patients receiving AEDs, over half (64.5%) used ≥3 different AEDs, and 22.5% underwent surgical treatment following AED initiation. Of the patients who underwent surgery, 35.1% had subsequent surgery. CONCLUSION: The use of multiple AEDs and surgical interventions may indicate a need for new therapies to reduce the treatment burden among patients with TSC and epilepsy.
INTRODUCTION:Tuberous sclerosis complex (TSC) is a rare congenital disorder often associated with epilepsy. However, real-world treatment patterns for epilepsy in patients with TSC are not yet well categorized. METHODS: This study included patients with TSC and epilepsy from fifteen clinics in the United States and one in Belgium who were enrolled in the TSC Natural History Database (2006-2014). Patient demographics and epilepsy treatment patterns, including the use of anti-epileptic drugs (AEDs), epilepsy surgeries, and dietary therapies were assessed. RESULTS: Of the 1328 patients with TSC in the database, 1110 (83.6%) were diagnosed with epilepsy. The median age of epilepsy diagnosis was 0.7 years. Of those who received treatment for epilepsy (92.3%), 99.5% were prescribed AEDs, 25.3% underwent surgery, 7.9% were prescribed special diets, and 1% were prescribed mammalian target of rapamycin (mTOR) inhibitors. Of the patients receiving AEDs, over half (64.5%) used ≥3 different AEDs, and 22.5% underwent surgical treatment following AED initiation. Of the patients who underwent surgery, 35.1% had subsequent surgery. CONCLUSION: The use of multiple AEDs and surgical interventions may indicate a need for new therapies to reduce the treatment burden among patients with TSC and epilepsy.
Authors: Johann Philipp Zöllner; David Neal Franz; Christoph Hertzberg; Rima Nabbout; Felix Rosenow; Matthias Sauter; Susanne Schubert-Bast; Adelheid Wiemer-Kruel; Adam Strzelczyk Journal: Orphanet J Rare Dis Date: 2020-01-21 Impact factor: 4.123
Authors: Tomas Petrasek; Iveta Vojtechova; Ondrej Klovrza; Klara Tuckova; Cestmir Vejmola; Jakub Rak; Anna Sulakova; Daniel Kaping; Nadine Bernhardt; Petrus J de Vries; Jakub Otahal; Robert Waltereit Journal: J Neurodev Disord Date: 2021-04-17 Impact factor: 4.025
Authors: Joyce Y Wu; Hannah R Cock; Orrin Devinsky; Charuta Joshi; Ian Miller; Colin M Roberts; Rocio Sanchez-Carpintero; Daniel Checketts; Farhad Sahebkar Journal: Epilepsia Date: 2022-03-04 Impact factor: 6.740
Authors: Elizabeth A Thiele; E Martina Bebin; Francis Filloux; Patrick Kwan; Rachael Loftus; Farhad Sahebkar; Steven Sparagana; James Wheless Journal: Epilepsia Date: 2021-12-27 Impact factor: 6.740